StemCor Systems, Inc., is located in Menlo Park, 25 miles south of San Francisco in the Bay Area. The privately held Company is developing enabling technologies for Regenerative Medicine. StemCor's flagship product is the MarrowMiner®, a proprietary, minimally-invasive bone marrow collection system. The technology is licensed exclusively from Stanford University.

The Company is currently in the clinical phase of development, evaluating the potential of the MarrowMiner to obtain sufficient and high quality marrow-derived cells. StemCor is led by individuals with over 100 years' of cumulative experience in medical device product development and engineering. Click here to view the Company's management team. Click here to view StemCor's Board of Directors.

Background

Bone marrow is a rich source of both adult stem and progenitor cells. Marrow-derived stem cells have been utilized extensively for over 40 years in the field of bone marrow transplantation, primarily for the treatment of a wide array of cancers and hematologic diseases for which over 60,000 transplants are performed each year.

Other potential therapeutic applications for adult bone marrow derived stem cells include: Orthopedic procedures such as spinal fusion and non-union fractures, Diabetic Ulcers, Cardiovascular Diseases such as Acute Myocardial Infarction (AMI) and Peripheral Arterial Disease (PAD), Diabetes and Neurodegenerative Diseases.

The Promise of Regenerative Medicine

Conventional pharmacological agents, biotech drugs and devices cannot repair or replace tissue or restore organ function lost due to injury, disease, age, and congenital defects. The promise of Regenerative Medicine is to create replacement tissue damaged or destroyed by physical trauma, disease or metabolic injury. To enable such revolutionary improvements in treatment options, physicians will need access to well-defined stem cell populations and the ability to concentrate and deliver these cells to the appropriate target. Current collection methods for bone marrow-derived stem cells are painful, requiring multiple needle punctures to collect small volumes of bone marrow from a donor’s hip bone that are eventually pooled, processed and re-implanted or re-infused. These collection procedures are laborious, resource-intensive and expensive, and in some clinical cases, require general anesthesia and hospitalization. Current marrow collection methods often deliver a diluted marrow aspirate, contaminated by peripheral blood, thus providing suboptimal material for therapeutic applications.

Additionally, the marrow aspirate often requires tedious, laboratory based, multi-step processing or concentration to enrich stem cell content, reducing cell numbers and viability, thus potentially diminishing therapeutic efficacy. Finally, there are few commercially available, site-specific stem cell delivery systems to administer stem cells to various target organs.

Therefore, an atraumatic, reliable, integrated solution that can seamlessly collect, process and deliver a concentrated sample of marrow derived stem cells at patient bedside we believe will greatly facilitate a broad array of personalized regenerative therapies that are currently not feasible.